Dr WU Dinglan    

0000-0002-5057-9626

Biography

Dr. Dinglan Wu is an Assistant Professor in the Department of Surgery, Faculty of medicine, the Chinese University of Hong Kong (CUHK). Dr. Wu obtained her PhD from CUHK (2009-2012), focusing on oncology research. Following her doctoral studies, she served as a postdoctoral fellow and research associate at CUHK (2013-2016) and as a Senior Visiting Scholar at Nanyang Technological University in 2022. Prior to joining CUHK as a faculty member, Dr. Wu held pivotal roles at the Clinical Innovation & Research Centre (CIRC) of Shenzhen Hospital, Southern Medical University, serving as an Associate Research Scientist, Research Scientist, and the Director of CIRC.

Dr. Wu research delves into the mechanisms of hormone resistance and bone metastasis in prostate cancer and tumor immune microenvironmentn of solid tumors, particular in glioblastoma. She has successfully led several projects funded by the National Natural Science Foundation of China (NSFC), the Guangdong Natural Science Foundation, and the Shenzhen Science and Technology Innovation Committee. She published more than 40 SCI papers in high-impact journals such as iScience, Nature Microbiology, The Journal for ImmunoTherapy of Cancer, Oncogene etc. She is also actively engaged in postgraduate education, supervising PhD, master's, and postdoctoral students.

Research Interests

• Hormone resistance and bone metastasis in prostate cancer
• Tumor Immune microenvironment and Immunotherapy
• Biomarkers and novel potential targets in solid tumor

Additional Information

Awards:

• First Class of Guangdong Province Science and Technology Progress Award (2023)
• Second Prize of the Chinese Medical Science and Technology Award (2022)
• Second Prize of Guangdong Medical Science and Technology Award (2022)

1. National Natural Science Foundation of China (NSFC), Elucidating the functional role of nuclear receptor TLX in promoting glioma stem cells to shape the immunosuppressive microenvironment, 2023-2026, PI, RMB 520,000
2. Shenzhen Science and technology innovation Commission, Preclinical study of a novel protein ligase to construet a theranostic anti-LRG1 nanobody for castration-resistant prostate cancer, 2024-2026, PI, RMB 1,500,000
3. National Natural Science Foundation of China (NSFC), “Elucidating the functional role of orphan nuclear receptor TLX in neuroendocrine prostate cancer”, 2019-2022, PI, RMB 570,000
4. Shenzhen Science and technology innovation Commission, “Screening and functional study resistance genes of PD-1 / PD-L1 therapy”, 2019-2022, PI, RMB 2,000,000
5. National Natural Science Foundation of China (NSFC) Youth Funding, “Elucidating the functional role of nuclear receptor TLX in prostate cancer stem cell maintenance”, 2016-2019, PI, RMB 180,000

Selected Publications

1. Lele Xu, Yuting Chen, Tao Wu, Jiaqi Fan, Yuying Hu, Xuefeng Gao, Yuliang Wang, Tao Chen, Xueting Zhao , Min Zeng, Fei Wang, Qingyou Zheng, Xiaojuan Pei, Dinglan Wu*. DNA damage-mediated FTO downregulation promotes CRPC progression by inhibiting FOXO3a via an m6A-dependent mechanism. iScience. 2024 Jul 14;27(8):110505. (*Corresponding authors, IF =6.107)
2. Sin Ting Chow, Jiaqi Fan, Xingxing Zhang, Jiaqi Fan, Yuliang Wang, Youjia Li, Chi-Fai Ng, Xiaojuan Pei, Qingyou Zheng, Fei Wang, Dinglan Wu *(11/12) and Franky Leung Chan *. Nuclear receptor TLX functions to promote cancer stemness and EMT in prostate cancer via its direct transactivation of CD44 and stem cell-regulatory transcription factors. Br J Cancer. 2024 2024 Sep 26. (* Corresponding authors, IF=9.075)
3. Yinggui Yang, Tengteng Ding, Ying Cong, Xiaomin Luo, Changlin Liu, Ting Gong, Min Zhao, Xichun Zheng, Chenglin Li, Yuanbin Zhang, Jiayi Zhou, Chuping Ni, Xueyu Zhang, Ziliang Ji, Tao Wu, Shaodong Yang, Qingchun Zhou, Dinglan Wu*, Xinqi Gong*, Qingyou Zheng*, Xin Li*. Interferon-induced transmembrane protein-1 competitively blocks Ephrin receptor A2-mediated Epstein–Barr virus entry into epithelial cells. Nature Microbiology 2024. May;9(5):1256-1270. (*Corresponding authors, IF =28.3)
4. Tao Chen , Jiangang Liu, Chenci Wang, Zhengwei Wang, Jiayi Zhou, Jiani Lin, Jie Mao, Tingzheng Pan, Jianwei Wang, Hongchao Xu, Xiaosheng He, Dinglan Wu, Zhuohao Liu*. ALOX5 contributes to glioma progression by promoting 5-HETE-mediated immunosuppressive M2 polarization and PD-L1 expression of glioma-associated microglia/macrophages. Journal for Immunotherapy of Cancer. 2024 Aug 13;12(8):e009492. (* Corresponding authors, IF=13.751)
5. Liu Z, Zhou J, Yang X, Liu Y, Zou C, Lv W, Chen C, Cheng KK, Chen T, Chang LJ, Wu D*, Mao*. Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma. Mol Cancer. 2023 Jan 9;22(1):3. (*Corresponding authors, IF =41.44)
6. Liu P, Wang W, Wang F, Fan J, Guo J, Wu T, Lu D, Zhou Q, Liu Z, Wang Y, Shang Z, Chan FL, Yang W, Li X, Zhao SC*, Zheng Q*, Wang F*, Wu D*. Alterations of plasma exosomal proteins and motabolies are associated with the progression of castration-resistant prostate cancer. J Transl Med. 2023 Jan 21;21(1):40. (*Corresponding authors, IF=8.44)
7. Gao W, Wang Y, Yu S, Wang Z, Ma T, Chan AM, Chiu PK, Ng CF, Wu D* , Chan FL* . Endothelial nitric oxide synthase (eNOS)-NO signaling axis functions to promote the growth of prostate cancer stem-like cells. Stem Cell Res Ther. 2022 May 7;13(1):188. (*Corresponding authors, IF=8.07)
8. Jiayi Zhou #, Xiaojuan Pei #, Yingui Yang #, Zhu Wang, Weijie Gao, Ran Ye, Jiangang Liu, Zhuohao Liu, Xinzhi Yang, Jingli Tao, Chunshan Gu, Wei Hu, Franky Leung Chan, Xin Li*, Jie Mao*, Dinglan Wu*. Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma. Journal for Immunotherapy of Cancer. 2021 Apr;9(4):e001937 (* Corresponding authors, IF=13.751)
9. Zhuohao Liu, Ruixiang Ge, Jiayi Zhou, Xinzhi Yang, Kenneth King-Yip Cheng, Jingli Tao, Dinglan Wu*, Jie Mao#. Nuclear Factor IX Promotes Glioblastoma Development Through Transcriptional Activation of Ezrin. Oncogenesis. 2020 Apr 14;9(4):39. ( *Corresponding authors，IF=7.485)
10. Jia L#, Wu Dinglan #,*, Wang Y#, You W , Wang Z, Xiao L, Cai G, Xu Z, Zou C, Wang F, Ng C F, Yu S and Chan FL* Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription. Oncogene. 2018 Mar. (#Co-first author, *Corresponding authors, IF=9.867)
11. Wang Z#, Wu Dinglan#, Ng CF, Teoh JY, Y u S, Wang YL, Chan FL*. Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer. Endocr Relat Cancer. 2018,25:1,35-50. (#Co-first author, IF=5.267)
12. Weijie Gao#, Dinglan Wu#, Yuliang Wang, Zhu Wang, Chi-Fai Ng, Jeremy Yuen-Chun Teoh,Franky Leung Chan*. Development of a novel and economical agar-based non-adherent three-dimensional culture method for enrichment of cancer stem-like cells. Stem Cell Res Ther. 2018 Sep 26;9(1):243. (IF=6.932)
13. Cai G#, Wu Dinglan#, Wang Z, Xu Z, Wong KB, Ng CF, Chan FL*, Yu S*. Collapsin response mediator protein-1 (CRMP1) acts as an invasion and metastasis suppressor of prostate cancer via its suppression of epithelial-mesenchymal transition and remodeling of actin cytoskeleton organization. Oncogene .2017 Jan 26;36(4):546-558. (#Co-first author, IF=9.867 )
14. Wu Dinglan#, Cheung A#, Wang Y, Shan Yu, Chan FL*. The emerging roles of orphan nuclear receptors in prostate cancer. BBA Reviews on Cancer. 2016 Aug;1866(1):23-36. (IF=10.68)
15. Wu Dinglan, Yu S, Jia L, Zou C, Xu Z, Xiao L, Wong KB, Ng CF, Chan FL. Orphan nuclear receptor TLX functions as a potent suppressor of oncogene-induced senescence in prostate cancer via its transcriptional co-regulation of CDKN1A (p21WAF1/CIP1) and SIRT1 genes. J Pathol. 2015 May;236(1):103-15. (IF=9.883)